clinical trial · NCT07134998
Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
Jiangsu HengRui Medicine Co., Ltd.·phase1·recruiting·n = 153
Advanced KRAS G12D Mutant Solid TumorsHRS-6093
brief summary
This is an open-label, multi-center phase I clinical study to evaluate HRS-6093 Safety, Tolerability, and Pharmacokinetics in Participants harboring KRAS G12D Mutations with advanced solid tumors. The study consists of dose escalation, dose expansion and efficacy expansion.
started
Sep 16, 2025
primary completion
May 1, 2028
completion
Dec 1, 2028
last updated
Dec 5, 2025
official title
A Phase I Study of HRS-6093 Evaluating Safety, Tolerability, and Pharmacokinetics in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol